What DiseaseSignal is — and isn't
Not medical advice. DiseaseSignal summarizes published biomedical research for general educational purposes only. Nothing here is medical advice, diagnosis, or treatment. Talk to a qualified healthcare professional about your own health. Do not start, stop, or change any treatment based on a briefing here.
What we do
Biomedical research moves faster than any one person can follow. DiseaseSignal reads the primary literature — journal papers, clinical-trial registries, and preprints — and turns notable findings into short, plain-English briefings across ten research sections.
What the Bottleneck Tracker adds
The Breakthrough Bottleneck Tracker follows unresolved research and implementation problems across time. Each entry identifies who encounters the friction, what current evidence supports, what remains missing, and the next result most likely to change confidence. Evidence-movement labels describe the bottleneck; they do not rate a treatment or predict benefit for an individual.
How we source
Every briefing is built from primary and authoritative sources — for example NCI, the NIH, ClinicalTrials.gov, FDA approval and safety materials, CDC, PubMed-indexed journals, UniProt and the PDB for structure, and preprint servers such as bioRxiv and medRxiv for early results. Each briefing links directly to the study it summarizes, and carries at least one structured citation (a PubMed ID or a DOI) so you can go straight to the source.
Skin & Dermatology briefings require independent primary studies. AAD clinical guidance, DermNet, MedlinePlus, and similar sources may clarify context, but they do not replace the primary-study evidence requirement.
Health Video Topics starts with a selected public X video to identify what is drawing attention, then builds a 600–1,000-word explainer from verified primary research. The X signal and its engagement metrics are displayed in a separate panel. They measure public attention, not medical evidence, truth, safety, or effectiveness, and they are never used as citations for medical claims.
How we handle uncertainty
- Preprints and early-stage results are labeled as such — they have not necessarily been peer-reviewed.
- Animal or cell-line findings are never described as if they apply to people.
- We report effect sizes and limitations, not just headlines, and we avoid implying a "cure" where the evidence does not support it.
What we will never do
- Give dosing, treatment, or diagnostic instructions.
- Fabricate statistics, quotes, citations, or study results.
- Overstate a preliminary finding as settled science.
Corrections
If a briefing misreads a source or a linked study is retracted, we correct or remove it. Accuracy against the primary source is the standard every briefing must pass before and after publication.